Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Circulating microRNAs and Their Role in Multiple Myeloma.

Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM.

Noncoding RNA. 2019 May 2;5(2). pii: E37. doi: 10.3390/ncrna5020037. Review.

2.

Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.

Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R.

Eur J Pharmacol. 2018 Nov 5;838:85-90. doi: 10.1016/j.ejphar.2018.09.014. Epub 2018 Sep 7.

3.

Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.

Gavazzoni M, Vizzardi E, Gorga E, Bonadei I, Rossi L, Belotti A, Rossi G, Ribolla R, Metra M, Raddino R.

Eur J Pharmacol. 2018 Jun 5;828:80-88. doi: 10.1016/j.ejphar.2018.03.022. Epub 2018 Mar 15. Review.

PMID:
29550338
4.

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. No abstract available.

PMID:
29479061
5.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
6.

Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission.

Parma M, ViganĂ² C, Fumagalli M, Colnaghi F, Colombo A, Mottadelli F, Rossi V, Elli E, Terruzzi E, Belotti A, Cazzaniga G, Pogliani EM, Pioltelli P.

Mediterr J Hematol Infect Dis. 2015 Jun 1;7(1):e2015041. doi: 10.4084/MJHID.2015.041. eCollection 2015.

7.

Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.

Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, Pogliani EM, Pioltelli PE.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.

PMID:
25468321
8.

Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.

Belotti A, Duca L, Borin L, Realini S, Renso R, Parma M, Pioltelli P, Pogliani E, Cappellini MD.

Leuk Res. 2015 Jan;39(1):88-91. doi: 10.1016/j.leukres.2014.11.003. Epub 2014 Nov 15.

PMID:
25435028
9.

Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.

Elli EM, Belotti A, Aroldi A, Parma M, Pioltelli P, Pogliani EM.

Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014042. doi: 10.4084/MJHID.2014.042. eCollection 2014.

10.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

11.

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.

Elli E, Cecchetti C, Belotti A, Borin L, Pogliani EM.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012017. doi: 10.4084/MJHID.2012.017. Epub 2012 Mar 13.

12.

Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.

Belotti A, Elli E, Speranza T, Lanzi E, Pioltelli P, Pogliani E.

Am J Hematol. 2012 Mar;87(3):319-20. doi: 10.1002/ajh.22264. Epub 2011 Dec 21.

Supplemental Content

Loading ...
Support Center